Prior Authorization Required for Covered HBOT Codes

Covered HBOT CPT/HCPCS codes require prior authorization and clinical selection criteria to be met before authorization is issued.

• Covered codes: CPT 99183 (physician attendance/supervision per session) and HCPCS G0277 (hyperbaric oxygen under pressure, full body chamber, per 30-minute interval)

Prior Conservative Therapy Required

Documentation must demonstrate prior adequate conservative management before HBOT is authorized for wound indications (e.g., diabetic foot ulcers). At minimum, document ≥1 month of meticulous wound care including assessment/optimization of vascular status, debridement, infection control, off-loading, glycemic control, nutritional optimization, and appropriate dressings.

• Failure to respond defined as no measurable signs of healing for ≥30 consecutive days
• Insufficient prior wound care documentation may lead to denial

Prior Authorization: Radiation‑Induced Hemorrhagic Cystitis

For radiation‑induced hemorrhagic cystitis (HC), prior authorization should document that guideline‑recommended conservative and alternative measures were attempted and failed before HBOT is considered; include prior therapies, timing, and clinical response.

• HBOT regimen in studies: ~90 minutes at ~2.2–2.4 ATA, average ~31–40 sessions
• Document prior intravesical or medical therapies and reason for failure

Prior Authorization: Indication and Prior Therapies Required

Prior authorization must be indication‑specific: submit the diagnosis, prior therapies and their outcomes, objective severity/stage, and supporting clinical evidence because trial data vary by indication.

• Provide indication‑specific evidence (RCTs, systematic reviews, case series) as applicable
• List prior therapies attempted and dates/outcomes

Prior Authorization: Timing and Prior Steroid Therapy for SSNHL

For idiopathic sudden sensorineural hearing loss (SSNHL), prior authorization should document timing of onset and prior steroid therapy (systemic and/or intra‑tympanic) because HBOT is considered an early adjunctive or salvage therapy.

• Document audiometry (pure‑tone audiogram showing ≥30 dB loss at 3 consecutive frequencies), date of onset, and timing/results of systemic and intra‑tympanic steroid therapy
• HBOT initiation generally within 3 months of onset in supporting protocols

HBOT Regimen Details Required for Prior Authorization

Prior authorization requests should include the proposed HBOT regimen (pressure, session duration, frequency, and total number of sessions) and plan for monitoring response and adverse events.

• Example regimens cited: 2.0–2.5 ATA, 60–90 minutes per session, once daily for up to 20–45 sessions depending on indication
• Specify planned frequency (e.g., once vs twice daily), total sessions, and stop/go criteria

Prior Authorization Not Specified in Background Material

Background and evidence summaries in this document do not themselves specify payer prior authorization steps; operational requirements are plan‑specific and governed by the Clinical Policy Bulletin and the payer.

• Clinical evidence sections summarize trials and do not set administrative rules
• Providers must follow plan-specific prior authorization processes

Insufficient Prior Wound Care Documentation May Lead to Denial

Absence of documentation of the required prior 1 month of meticulous wound care or failure to provide photographic documentation (with ruler) and objective perfusion testing (TcPO2/TCOM) may lead to denial of HBOT for diabetic or other wound indications.

• Photographic wound documentation at baseline and after every 15 treatments or at least every 30 days
• Provide TcPO2/TCOM results and normobaric oxygen challenge when available

Evidence‑Quality Related Denial Risk

Evidence limitations and trials at unclear or high risk of bias for many indications may lead to authorization denials or requests for additional justification; indicate the strength/quality of supporting evidence in requests.

• Denial risk higher for indications supported only by small, nonrandomized, or low‑quality studies
• Include RCT data when available and explain how patient matches studied populations

Insufficient Evidence for CRAO; Denial Risk

Central retinal artery occlusion (CRAO) lacks robust evidence and consensus on timing/benefit; authorization may be denied or require strong justification and acute presentation timing documentation.

• Case reports/series show mixed results; larger studies/guidelines are lacking
• Document time from symptom onset and ophthalmology evaluations if requesting HBOT for CRAO

Post‑Concussive Syndrome — Negative RCT Evidence

Randomized sham‑controlled trials for post‑concussive syndrome (PCS) have found no benefit of HBOT over sham in several high‑quality trials; prior authorization may be denied for chronic PCS absent compelling new evidence.

• Cited RCTs (Cifu 2014; Miller 2015) showed no between‑group benefit versus sham
• Provide RCT-level justification if requesting HBOT for PCS

Chronic Bowel Dysfunction — Negative RCT (HOT2)

For chronic bowel dysfunction after pelvic radiotherapy, a randomized sham‑controlled trial (HOT2) found no benefit of HBOT; authorization for this indication should be supported by strong, case‑specific justification or may be denied.

• HOT2: 40 exposures (90 min) at 2.4 ATA showed no significant improvement in primary IBDQ endpoints at 12 months
• Document prior ≥3 months of optimal medical therapy and lack of cancer recurrence when requesting HBOT for this indication

Mechanistic/Preclinical Indications — Provide Clinical Justification

Many indications remain supported mainly by mechanistic or preclinical data; when clinical evidence is lacking, prior authorization should include clinical justification linking patient condition to plausible benefit and note investigational status.

• For mechanistic/preclinical indications (e.g., some surgical prophylaxis, animal models), explain rationale and cite any human data
• Providers should expect higher scrutiny or denial for indications lacking human efficacy data

Failure to Improve with HBOT May Require Conversion to Alternative Therapies

If a patient fails to improve with HBOT as documented by objective measures (photography, wound size, TcPO2), prior authorization for continuation may be denied and conversion to alternative therapies (e.g., decompression/tube therapy for SBO or surgical options) may be required.

• Continued HBOT not medically necessary if no measurable signs of healing within any 30‑day period
• For adhesive postoperative SBO, document if decompression/tube therapy was used or considered after HBOT failure

Low TcPO2/TCOM Predicts HBOT Failure — Include Results

Low transcutaneous oxygen (TcPO2/TCOM) or poor response to normobaric oxygen challenge predicts HBOT failure; include these test results in prior authorization requests for wounds.

• Normobaric oxygen challenge: TcPO2 <35 mmHg or increase <10 mmHg predicts ~89% failure rate with HBOT
• In-chamber TcPO2 <50 mmHg is almost always associated with HBOT failure; report TcPO2 values

Background/References: No Authorization Requirements Present

Some sections of this document are background, references, or appendices and do not impose operational authorization requirements; they summarize evidence and trials only.

• Background and References sections: no administrative requirements specified
• Appendix contains Wagner grading, TcPO2 guidance and documentation requirements

Administrative Note: Provider Responsibility and Plan‑Specific Rules

Administrative note: Clinical Policy Bulletins assist in administering plan benefits and do not constitute coverage guarantees. Providers are responsible for following plan‑specific prior authorization processes and documenting compliance with the CPB criteria when submitting requests.

• CPB is guidance for policy administration; follow the payer's prior authorization portal/process
• Providers (not Aetna) are responsible for medical management and documentation submission

Study Regimen and Required Documentation for Peri‑Anal Fistula Pilot and Similar Trials

Study protocols or pilot trial regimens (e.g., peri‑anal fistula pilot) should be submitted with prior authorization requests when relevant; include protocol details, number of sessions, pressure, and planned assessments.

• Example: peri‑anal fistula pilot — 40 sessions at 243–253 kPa with assessment at baseline, 16, 34, and 60 weeks
• Attach study protocol or IRB documentation when requesting coverage for trial‑like regimens

Adjunctive Use / Stepwise Care Required

Adjunctive use and stepwise care: HBOT should be adjunctive and not replace standard therapies; prior authorization should document coordination with other treatments and that standard/less invasive options were tried and exhausted as appropriate.

• For radiation‑related conditions, document exhaustion of guideline‑recommended alternatives (e.g., IMRT, amifostine)
• For ONJ and complex conditions, document multimodal therapy (surgery/antibiotics) prior to HBOT

Adjunctive Topical/Vaporous Oxygen Therapies — Investigational; Document Rationale

Adjunctive topical or vaporous oxygen therapies are considered investigational in this CPB; if such therapies are proposed, prior authorization must include rationale and acknowledgement of investigational status.

• Topical hyperbaric oxygen (A4575), topical oxygen delivery systems (E0446) and vaporous hyperoxia therapy are listed as not covered or investigational
• Provide strong clinical justification and trial data if requesting coverage for nonstandard topical/vapor therapies